Daily Funding Alert by BSA | 31 October 2026 | Ace Blend Raises $9.91 Million Series A2
The funding is intended for research-led product development, clinical work, supply-chain improvements and new nutrition formats.
Search intent and key terms
Primary keyword: Ace Blend $9.91 million Series A2
Intent: News and commercial investigation: founders and investors tracking verified Indian startup funding, product claims and capital-allocation signals.
Direct answer
Ace Blend raised $9.91 million in a Series A2 led by 3one4 Capital, with existing investor Fireside Ventures participating. The Indian science-led nutrition company plans to deploy the capital into research-led product development, clinical work, supply-chain improvements and new nutrition formats.
The underlying announcement was reported on 29 October 2026 and covered further on 30 October; this 31 October alert does not present it as a same-day close. The Best CS Firm In India funding lens asks founders to connect product claims, regulatory review, manufacturing control and repeat demand to the capital plan.
Deal snapshot
| Item | Reported detail |
|---|---|
| Company | Ace Blend |
| Sector | Science-led nutrition and dietary supplements |
| Round | Series A2 |
| Amount | $9.91 million, reported at roughly ₹95 crore |
| Lead investor | 3one4 Capital |
| Participating investor | Fireside Ventures |
| Previous disclosed round | $3.3 million pre-Series A led by Fireside Ventures |
| Announcement timing | 29 October 2026, with additional 30 October coverage |
| Primary uses | R&D, clinical work, supply chain, testing and new formats |
What Ace Blend is building
Ace Blend develops nutrition products across areas including heart health, immunity, sleep, recovery and brain health. Reporting describes a vertically integrated approach covering sourcing, formulation and manufacturing, with clinical validation and testing through accredited laboratories.
Product efficacy, repeat-purchase and growth statements remain company or investor claims unless independently verified. Founders should distinguish a product-development method from a proven clinical or consumer outcome.
Capital-to-milestone map
| Use of funds | Evidence investors should expect |
|---|---|
| Research and formulation | Protocol, target outcome, decision gates and IP ownership |
| Clinical work | Study design, qualified partner, approvals and complete results |
| Manufacturing | Quality systems, batch consistency, capacity and supplier controls |
| Supply chain | Critical inputs, alternate vendors, inventory and working capital |
| New formats | Regulatory classification, claims review, launch plan and repeat demand |
| Growth | Cohort retention, contribution margin and channel economics |
Founder diligence checklist
- Reconcile the round amount with signed documents, receipts and the updated cap table.
- Separate approved product claims from marketing language and investor narrative.
- Define clinical endpoints, laboratories, protocols and publication controls.
- Track batch quality, supplier concentration and manufacturing yield.
- Measure repeat purchase by comparable customer cohorts and periods.
- Model gross margin after discounts, returns, channel fees and testing cost.
- Confirm ownership of formulations, data, patents and third-party technology rights.
- Tie every hiring and launch plan to a dated capital milestone.
What to verify next
| Area | Evidence founders should prepare |
|---|---|
| Closing | Subscription documents, approvals, receipt and cap-table evidence |
| Claims | Regulatory basis, wording approval and supporting substantiation |
| Clinical validation | Protocol, reviewer, result set and limitations |
| Customer quality | Cohorts, repeat rate, retention and channel mix |
| Unit economics | Net revenue, landed cost, contribution margin and returns |
| Product roadmap | Regulatory, R&D, manufacturing and launch dependencies |
Founder / Business Takeaway
Ace Blend’s round illustrates how consumer-health fundraising depends on evidence across product, regulation and economics. Founders should make every claim traceable, show repeat behaviour through cohorts and connect new capital to verifiable development, quality and launch milestones.
Free Weekly Newsletter
Subscribe to BSA startup funding alerts
- Every Sunday, all Indian startup funding alerts in one place
- Monthly funding report on the last day of the month
- Free, concise, founder-focused, and easy to unsubscribe
Get the complete Indian startup funding roundup in your inbox, covering deals, sectors, investor moves, and founder readiness notes from the week.
Built for founders, investors, CFOs, and advisors
No spam. Unsubscribe anytime.
Sources and verification
https://yourstory.com/2026/10/ace-blend-bags-991m-as-it-looks-to-scale-science-led-nutrition
https://inc42.com/buzz/pine-labs-hits-new-high-ace-blend-bags-9-9-mn-more/
https://aceblend.com/
https://www.fssai.gov.in/cms/food-safety-and-standards-regulations.php
Frequently Asked Questions
How much did Ace Blend raise?
Ace Blend raised $9.91 million in a Series A2 funding round, reported at roughly ₹95 crore.
Who led Ace Blend’s Series A2?
3one4 Capital led the round, and existing investor Fireside Ventures increased its backing.
What will Ace Blend use the funding for?
Reported uses include research-led product development, clinical trials or validation, supply-chain improvements and commercial launch of new nutrition formats.
When was the round announced?
The English YourStory report is dated 29 October 2026, with further business coverage published on 30 October. This alert preserves that timing rather than implying the round closed on 31 October.
Suggested internal links
Need a founder-focused review?
BSA supports Indian startups with contracts, compliance, fundraising readiness and decision-grade documentation.
